Table 4.
Predictors of reaching NEDA-3 in patients treated with glatiramer acetate or dimethyl fumarate by univariate logistic regression analysis.
| Variable | OR | 95% CI | p |
|---|---|---|---|
| Disease duration | 0.96 | 0.89–1.04 | 0.311 |
| Gender | 1.62 | 0.67–3.92 | 0.285 |
| Age | 1.02 | 0.99–1.05 | 0.249 |
| Baseline EDSS score | 1.19 | 0.84–1.70 | 0.321 |
| Unique CSF OCB | 1.42 | 0.68–2.92 | 0.521 |
| Number of relapses before LP | 0.97 | 0.59–1.58 | 0.894 |
| CSF detectability of PDGF | 0.57 | 0.22–1.46 | 0.243 |
| CSF detectability of MIP-1α | 2.48 | 0.21–8.61 | 0.268 |
*
Other non-significant correlations with CSF molecules are not reported.
CI, confidence interval; CSF, cerebrospinal fluid; EDSS, expanded disability status scale; LP, lumbar puncture; MIP-1α, macrophage inflammatory protein-1α; NEDA, no evidence of disease activity; OCB, oligoclonal bands; OR, odds ratio; PDGF, platelet-derived growth factor.